Thiazolidinediones Regulate Adipose Lineage Dynamics

• Published in: Cell metabolism Vol. 14; no. 1; pp. 116 - 122
• Main Authors: Tang, Wei, Zeve, Daniel, Seo, Jin, Jo, A-Young, Graff, Jonathan M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 06.07.2011
• Subjects: Adipocytes - cytology; Adipocytes - metabolism; Adipose Tissue, White - cytology; Adipose Tissue, White - drug effects; Animals; Cell Differentiation; Cell Lineage; Cell Proliferation; Mice; Stem Cells - cytology; Stem Cells - metabolism; Thiazolidinediones - pharmacology
• ISSN: 1550-4131; 1932-7420
• DOI: 10.1016/j.cmet.2011.05.012

White adipose tissue regulates metabolism; the importance of this control is highlighted by the ongoing pandemic of obesity and associated complications such as diabetes, atherosclerosis, and cancer. White adipose tissue maintenance is a dynamic process, yet very little is known about how pharmacologic stimuli affect such plasticity. Combining in vivo lineage marking and BrdU labeling strategies, we found that rosiglitazone, a member of the thiazolidinedione class of glucose-lowering medicines, markedly increases the evolution of adipose progenitors into adipocytes. Notably, chronic rosiglitazone administration disrupts the adipogenic and self-renewal capacities of the stem cell compartment and alters its molecular characteristics. These data unravel unknown aspects of adipose dynamics and provide a basis to manipulate the adipose lineage for therapeutic ends. ► Thiazolidinediones (TZDs) stimulate new adipocyte formation in white adipose tissue ► TZDs stimulate the proliferation and differentiation of adipose progenitors ► Chronic TZD treatment disrupts the progenitor properties ► TZDs alter the molecular characteristics of adipose progenitors